DIVI S LABORATORIES LTD (532488) — Latest Corporate Announcements
₹9,210.5
₹-215.50 (-2.29%)
Market Cap
₹2,44,509.84 Cr
P/E Ratio
84.35
52W Range
₹5647.5 – ₹9740
Corporate Actions & Regulatory Filings
Divis Laboratories Ltd - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
To consider and approve the financial results for the period ended December 31, 2025
To consider and approve the financial results for the period ended September 30, 2025
To consider and approve the financial results for the period ended Jun 30, 2025
To consider and approve the financial results for the period ended March 31, 2025 and dividend
To consider and approve the financial results for the period ended December 31, 2024
To consider and approve the financial results for the period ended September 30, 2024
To consider and approve the financial results for the period ended Jun 30, 2024
To consider and approve the financial results for the period ended March 31, 2024 and dividend
To consider and approve the financial results for the period ended December 31, 2023
To consider and approve the financial results for the period ended September 30, 2023
To consider and approve the financial results for the period ended Jun 30, 2023
To consider and approve the financial results for the period ended March 31, 2023 and dividend
To consider and approve the financial results for the period ended December 31, 2022
Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2022 to consider financial statements for the period ended September 2022
Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 12-Aug-2022 to consider financial statements for the period ended June 2022
DIVISLAB : 11-Feb-2022 : The Company has informed the Exchange that a Board meeting to be held on February 04, 2022 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on February 11, 2022, To consider and approve the financial results for the period ended December 31, 2021
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 01-Aug-2026 | Declared | To consider and approve the financial results for the period ended Jun 30, 2026 |
| Year Ended 31-Mar-2026 (Q4 FY26) | 23-May-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 11-Feb-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 07-Nov-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025 |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 06-Aug-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 17-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 03-Feb-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 09-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 03-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 25-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 10-Feb-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 06-Nov-2023 | Declared | To consider and approve the financial results for the period ended September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about DIVI S LABORATORIES LTD BSE Disclosures
What is the latest BSE announcement by DIVI S LABORATORIES LTD?
The latest BSE disclosure by DIVI S LABORATORIES LTD (DIVISLAB), filed on 2026-10-06T12:22:08, is: "Divis Laboratories Ltd - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018". Bsenexus tracks every official filing for DIVI S LABORATORIES LTD with AI-powered summaries on its announcements feed.
When is DIVI S LABORATORIES LTD's next board meeting?
No upcoming board meeting is currently tracked for DIVI S LABORATORIES LTD. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.
When does DIVI S LABORATORIES LTD declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. DIVI S LABORATORIES LTD's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.